ProPhase Labs Inc. (PRPH)
ProPhase Labs Statistics
Share Statistics
ProPhase Labs has 29.87M shares outstanding. The number of shares has increased by 32.3% in one year.
Shares Outstanding | 29.87M |
Shares Change (YoY) | 32.3% |
Shares Change (QoQ) | 25.14% |
Owned by Institutions (%) | 12.68% |
Shares Floating | 26.37M |
Failed to Deliver (FTD) Shares | 509 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 154.06K, so 0.65% of the outstanding shares have been sold short.
Short Interest | 154.06K |
Short % of Shares Out | 0.65% |
Short % of Float | 0.75% |
Short Ratio (days to cover) | 7.04 |
Valuation Ratios
The PE ratio is -2.32 and the forward PE ratio is -0.59. ProPhase Labs's PEG ratio is 0.01.
PE Ratio | -2.32 |
Forward PE | -0.59 |
PS Ratio | 0.88 |
Forward PS | 0.3 |
PB Ratio | 0.79 |
P/FCF Ratio | -2.68 |
PEG Ratio | 0.01 |
Enterprise Valuation
ProPhase Labs Inc. has an Enterprise Value (EV) of 97.01M.
EV / Earnings | -5.78 |
EV / Sales | 2.19 |
EV / EBITDA | -6.54 |
EV / EBIT | -4.49 |
EV / FCF | -6.69 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.43.
Current Ratio | 2.28 |
Quick Ratio | 2.1 |
Debt / Equity | 0.43 |
Total Debt / Capitalization | 30.21 |
Cash Flow / Debt | -0.53 |
Interest Coverage | -16.95 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -22.48%.
Return on Equity (ROE) | -0.34% |
Return on Assets (ROA) | -0.18% |
Return on Capital (ROIC) | -22.48% |
Revenue Per Employee | $392,778.76 |
Profits Per Employee | $-148,513.27 |
Employee Count | 113 |
Asset Turnover | 0.48 |
Inventory Turnover | 7.33 |
Taxes
Income Tax | -6.02M |
Effective Tax Rate | 0.26 |
Stock Price Statistics
The stock price has increased by -85.49% in the last 52 weeks. The beta is -0.51, so ProPhase Labs's price volatility has been lower than the market average.
Beta | -0.51 |
52-Week Price Change | -85.49% |
50-Day Moving Average | 0.42 |
200-Day Moving Average | 1.03 |
Relative Strength Index (RSI) | 53.83 |
Average Volume (20 Days) | 10.09M |
Income Statement
In the last 12 months, ProPhase Labs had revenue of 44.38M and earned -16.78M in profits. Earnings per share was -0.98.
Revenue | 44.38M |
Gross Profit | 16.24M |
Operating Income | -21.61M |
Net Income | -16.78M |
EBITDA | -14.83M |
EBIT | -21.61M |
Earnings Per Share (EPS) | -0.98 |
Balance Sheet
The company has 1.61M in cash and 21.38M in debt, giving a net cash position of -19.77M.
Cash & Cash Equivalents | 1.61M |
Total Debt | 21.38M |
Net Cash | -19.77M |
Retained Earnings | -5.03M |
Total Assets | 91.81M |
Working Capital | 13.54M |
Cash Flow
In the last 12 months, operating cash flow was -11.35M and capital expenditures -3.15M, giving a free cash flow of -14.5M.
Operating Cash Flow | -11.35M |
Capital Expenditures | -3.15M |
Free Cash Flow | -14.5M |
FCF Per Share | -0.84 |
Margins
Gross margin is 36.59%, with operating and profit margins of -48.7% and -37.81%.
Gross Margin | 36.59% |
Operating Margin | -48.7% |
Pretax Margin | -51.37% |
Profit Margin | -37.81% |
EBITDA Margin | -33.41% |
EBIT Margin | -48.7% |
FCF Margin | -32.68% |
Dividends & Yields
PRPH pays an annual dividend of $0.9, which amounts to a dividend yield of 14.35%.
Dividend Per Share | $0.90 |
Dividend Yield | 14.35% |
Dividend Growth (YoY) | 0% |
Payout Ratio | -58.82% |
Earnings Yield | -208.51% |
FCF Yield | -104.4% |
Analyst Forecast
Currently there are no analyst rating for PRPH.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 23, 1997. It was a forward split with a ratio of 2:1.
Last Split Date | Jan 23, 1997 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | -1.16 |
Piotroski F-Score | 1 |